Table 1. Clinical characteristics of the CLL samples used.
| Sample number | Sex | Age at diagnosis | Stage (Binet) | WBC (109/l) | IGHV status¶ | Chromosomal abnormalities | Prior therapy* |
|---|---|---|---|---|---|---|---|
| #1958 | f | 65 | A | 215 | M | 13q- | Y |
| #2064 | m | 46 | C | 120 | UM | Tri12 | Y |
| #2096 | m | 65 | A | 60 | M | 17p- & 13q- | N |
| #2103 | m | 56 | A | 125 | UM | 17p- & 13q- | N |
| #2263 | m | 65 | B | 366 | UM | 11q- & 13q- | Y |
| #2521 | f | 79 | B | 74 | M | Tri12 | Y |
| #2729 | m | 66 | A | 37 | M | normal | N |
| #2804 | F | nd# | A | 39.7 | M | nd | nd |
| #2814 | m | 72 | A | 196 | UM | normal | N |
| #2996 | m | nd | nd | 169.2 | M | 13q- | nd |
| #3033 | m | 66 | A | 41 | M | normal | N |
| #3058 | m | 69 | B | 51 | UM | normal | N |
| #3091 | m | nd | nd | 41.7 | UM | 11q- | nd |
| #3106 | m | 66 | C | 115 | UM | 11q- & 13q- | nd |
| #3129 | m | nd | nd | 31.8 | UM | nd | nd |
| #3308 | m | 66 | C | nd | UM | nd | nd |
| #3353 | f | 75 | A | 72 | M | nd | nd |
| #3355 | m | 73 | B | 130 | M | 13q- | nd |
| #3365 | f | nd | C | 253 | nd | 13q- | nd |
| #3379 | m | 67 | B | 228.5 | UM | 17p- | Y |
¶IGHV status refers to somatic mutation in IGHV gene of CLL cells as compared with the gene sequence of the nearest germ-line using 2% as a cut-off. M=mutated; UM=un-mutated.
*Prior therapy consisted of various combinations of glucocorticoid, chlorambucil, fludarabine, or fludarabine plus cyclophosphamide.
#nd: not done/unknown